A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP
Figure 7
Changes in score of ADL. Each plot refers to mean ± SD. *Significant difference between the score on day 1 and day 14 in the TJ-43 non-treated group (< 0.05, Wilcoxon’s signed rank test).